Market Place
Sourcing Support
Vaxart To Present At Oppenheimer Healthcare Life Sciences
18 Feb 2026 //
GLOBENEWSWIRE
Does Vaxart Hold The Key To The Elusive Norovirus Vaccine?
17 Feb 2026 //
BIOSPACE
Vaxart Releases Positive Data On Oral Norovirus Vaccine
15 Jan 2026 //
GLOBENEWSWIRE
Vaxart Joins Global Bioinnovation Forum On Jan 13, 2026
08 Jan 2026 //
GLOBENEWSWIRE
Dynavax Enters License Agreement for Vaxart`s Oral COVID Vaccine
05 Nov 2025 //
PR NEWSWIRE
Vaxart To Showcase Next-Gen Norovirus Oral Vaccine At Idweek 2025
20 Oct 2025 //
GLOBENEWSWIRE
Vaxart To Showcase Oral COVID-19 & Norovirus Vaccines At WVC 2025
08 Oct 2025 //
GLOBENEWSWIRE
Vaxart Withdraws Reverse Stock Split Proposal
19 Sep 2025 //
GLOBENEWSWIRE
Vaxart Appoints W. Mark Watson as Lead Independent Director
17 Sep 2025 //
GLOBENEWSWIRE
Vaxart Reveals Phase 1 Data Support Efficacy of Oral Pill Vaccine
10 Sep 2025 //
GLOBENEWSWIRE
Vaxart to Present at H.C. Wainwright Global Investment Conference
03 Sep 2025 //
GLOBENEWSWIRE
Vaxart Chairman Michael J. Finney, Ph.D. Retires from Board
02 Sep 2025 //
GLOBENEWSWIRE
Vaxart Granted Extension by Nasdaq to Regain Compliance
29 Aug 2025 //
GLOBENEWSWIRE
Vaxart to host virtual fireside chat on reverse stock split
14 Aug 2025 //
GLOBENEWSWIRE
US orders Vaxart to Stop COVID-19 trial Amid mRNA Wind Down
14 Aug 2025 //
REUTERS
HHS Freezes Vaxart’s Oral COVID-19 Vaccine, Again
13 Aug 2025 //
BIOSPACE
Vaxart CEO`s Letter to Stockholders
08 Aug 2025 //
GLOBENEWSWIRE
Vaxart Proposes Reverse Stock Split for Nasdaq Trading Resumption
24 Jul 2025 //
GLOBENEWSWIRE
Vaxart Begins Trading on OTCQX Best Market
08 Jul 2025 //
GLOBENEWSWIRE
Vaxart Announces Stockholders Meeting Results
13 Jun 2025 //
GLOBENEWSWIRE
Vaxart`s Second-Gen Vaccine Tech Shows Stronger Antibody Response
11 Jun 2025 //
GLOBENEWSWIRE
Vaxart to Host Call on June 11 to Discuss Phase I Trial Results
10 Jun 2025 //
GLOBENEWSWIRE
Vaxart at Jefferies Global Healthcare Conference on June 5, 2025
29 May 2025 //
GLOBENEWSWIRE
Vaxart Starts Dosing in 10,000-Participant Ph 2b COVID-19 Trial
27 May 2025 //
GLOBENEWSWIRE
Vaxart Announces Adjournment of Annual Meeting of Stockholders
21 May 2025 //
GLOBENEWSWIRE
Vaxart Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
20 May 2025 //
GLOBENEWSWIRE
Vaxart Publishes Positive Phase 2b Norovirus Vaccine Results
14 May 2025 //
GLOBENEWSWIRE
Vaxart CEO Updates Stockholders on Company Progress
05 May 2025 //
GLOBENEWSWIRE
Vaxart Completes Ph 1 Trial Enrollment for Norovirus Pill vaccine
30 Apr 2025 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine Congress Washington 2025
16 Apr 2025 //
GLOBENEWSWIRE
Vaxart lays off staffers after HHS demands halt to vaccine trial
21 Mar 2025 //
FIERCE BIOTECH
Vaxart Starts Norovirus Oral Pill Vaccine Trial
11 Mar 2025 //
GLOBENEWSWIRE
Vaxart Announces Publication on Oral Norovirus Vaccine in Elderly
05 Mar 2025 //
GLOBENEWSWIRE
Vaxart Appoints Biotech Executive Kevin to Board of Directors
28 Jan 2025 //
GLOBENEWSWIRE
Vaxart Highlights Progress In COVID-19 And Norovirus Programs
14 Jan 2025 //
GLOBENEWSWIRE
Vaxart Announces Favorable DSMB Review For COVID-19 Phase 2b Trial
13 Jan 2025 //
GLOBENEWSWIRE
Vaxart Completes Enrollment In Phase 2b COVID-19 Oral Vaccine Study
02 Dec 2024 //
GLOBENEWSWIRE
Vaxart To Showcase COVID-19 And Norovirus Vaccines At Congress
24 Oct 2024 //
GLOBENEWSWIRE
Vaxart To Present Norovirus Data At IDWeek 2024
15 Oct 2024 //
GLOBENEWSWIRE
Vaxart Initiates Sentinel Cohort For Ph 2b COVID-19 Pill Vaccine
30 Sep 2024 //
GLOBENEWSWIRE
Vaxart Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Vaxart wins $453M in BARDA funding for oral Covid-19 vaccine
14 Jun 2024 //
ENDPTS
Vaxart Gets BARDA Award Up To $453M For COVID-19 Oral Pill Vaccine Study
13 Jun 2024 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
13 May 2024 //
GLOBENEWSWIRE
Vaxart: Positive Bivalent Norovirus Vaccine Data In Lactating Mothers
30 Apr 2024 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
27 Mar 2024 //
GLOBENEWSWIRE
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data
05 Feb 2024 //
GLOBENEWSWIRE
Vaxart Announces Last Subject Dosed in Phase 1 of Norovirus Vaccine Candidate
21 Dec 2023 //
GLOBENEWSWIRE
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate
02 Nov 2023 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
11 Oct 2023 //
GLOBENEWSWIRE
Vaxart norovirus vaccine has mixed success in midphase test
07 Sep 2023 //
FIERCE BIOTECH
Vaxart Announces Data from Ph 2 Study of Monovalent Norovirus Vaccine Candidate
06 Sep 2023 //
GLOBENEWSWIRE
Vaxart Provides Business Update & Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Vaxart`s oral norovirus vax spurs immune response in ph. 2 trial
06 Jul 2023 //
FIERCE BIOTECH
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Ph2 Study
06 Jul 2023 //
GLOBENEWSWIRE
Vaxart Announces Subject Dosed in Phase 2 Trial of Bivalent Norovirus Candidate
06 Jun 2023 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
04 May 2023 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
29 Mar 2023 //
GLOBENEWSWIRE
Vaxart cans oral COVID-19 vaccine plans, lays off 27% of staff
16 Mar 2023 //
FIERCE BIOTECH
